Expression of metalloproteinases and their inhibitors in adenocarcinoma of the uterine cervix

International Journal of Gynecological Pathology

Volumn 17, Issue 4, 1998, Pages 295-301

  Davidson, Ben ^a,d   Goldberg, Iris ^a   Liokumovich, Pavel ^a   Kopolovic, Juri ^a   Gotlieb, Walter H ^a   Lerner Geva, Liat ^a   Reder, Ilan ^a   Ben Baruch, Gilad ^a   Reich, Reuven ^b,c  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Adenocarcinoma; Human papillomavirus; Metalloproteinases; Uterine cervix

Indexed keywords

GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; MESSENGER RNA; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; EXTRACELLULAR MATRIX; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; UTERINE CERVIX CARCINOMA; UTERINE CERVIX EPITHELIUM; UTERINE ENDOCERVIX; WART VIRUS;

EID: 0031716731     PISSN: 02771691     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004347-199810000-00002     Document Type: Article

References (37)

1. Liotta LA, Rao CN, Barsky SH. Tumor invasion and the extracellular matrix. Lab Invest 1983;49:636-49.
2. Crawford HC, Matrisian LN. Tumor and stromal expression of matrix metalloproteinases and their role in tumor progression. Invasion Metastasis 1994-5;14:234-45.
3. Aznavoorian S, Murphy AN, Stetler-Stevenson WG, Liotta LA. Molecular aspects of tumor cell invasion and metastasis. Cancer 1993;71:1368-83.
4. Matrisian LM. The matrix-degrading metalloproteinases. Bioassays 1992;14:455-63.
5. Liotta LA, Stetler-Stevenson WG. Tumor invasion and metastasis: An imbalance of positive and negative regulation. Cancer Res 1991;51:5054-9s.
6. Tryggvason K, Hoyhtya M, Pyke C. Type IV collagenases in invasive tumors. Breast Cancer Res Treat 1993;24:209-18.
7. Furcht LT, Skubitz APN, Fields GB. Tumor cell invasion, matrix metalloproteinases, and the dogma (Editorial). Lab Invest 1994; 70:781-3.
8. Stetler-Stevenson WG. Dynamics of matrix turnover during pathologic remodeling of the extracellular matrix. Am J Pathol 1996; 148:1345-50.
9. Himelstein BP, Canete-Soler R, Bernhard EJ, Dilks DW, Muschel RJ. Metalloproteinases in tumor progression: the contribution of MMP-9. Invasion Metastasis 1994-5;14:246-258.
10. Stetler-Stevenson WG, Brown PD, Onisto M, Levy AT, Liotta LA. Tissue inhibitor of metalloproteinases-2 (TIMP-2) mRNA expression in tumor cell lines and human tumor tissues. J Biol Chem 1990;265:13933-8.
11. Powe DG, Brough JL, Carter GI, Bailey EM, Stetler-Stevenson WG, Turner DP, Hewitt RE. TIMP-3 mRNA expression is regionally increased in moderately and poorly differentiated colorectal carcinoma. Br J Cancer 1997;75:1678-83.
12. Lokeshwar BL, Selzer MG, Block NL, Gunja SZ. Secretion of matrix metalloproteinases and their inhibitors (tissue inhibitor of metalloproteinases) by human prostate in explant cultures: Reduced tissue inhibitor of metalloproteinase secretion by malignant tissues. Cancer Res 1993;53:4493-8.
13. Murphy G, Docherty AJP. The matrix metalloproteinases and their inhibitors. Am J Respir Cell Mol Biol 1992;30:8097-8102.
14. Nuovo GJ, MacConnel PB, Simsir A, Valea F, French DL. Correlation of the in situ detection of polymerase chain reaction-amplified metalloproteinase complementary DNAs and their inhibitors with prognosis in cervical carcinoma. Cancer Res 1995; 55:267-75.
15. Visscher DW, Hoyhtya M, Ottosen SK, Liang CM, Sarkar FH, Crissman JD, Fridman R. Enhanced expression of tissue inhibitor of metalloproteinase-2 (TIMP-2) in the stroma of breast carcinomas correlates with tumor recurrence. Int J Cancer 1994;59:339-44.
16. Kobayashi T, Onoda N, Takagi T, et al. Immunolocalization of human gelatinase (type IV collagenase, MMP-9) and TIMP (tissue inhibitor of metalloproteinases) in normal epidermis and some epidermal tumors. Arch Dermatol Res 1996;288:239-44.
17. Nakagawa T, Kubota T, Kabuto M, Sato K, Kawano H, Hayakawa T, Okada Y. Production of matrix metalloproteinases and tissue inhibitor of metalloproteinases-1 by human brain tumors. J Neurosurg 1994;81:69-77.
18. Miller BE, Flax SD, Arheart K, Photopulos G. The presentation of adenocarcinoma of the uterine cervix. Cancer 1993;72:1281-5.
19. Shorrock K, Johnson J, Johnson IR. Epidemiological changes in cervical carcinoma with particular reference to mucin-secreting subtypes. Histopathology 1990;17:53-7.
20. Vesterinen E, Forss M, Nieminen U. Increase of cervical adenocarcinoma: a report of 520 cases of cervical carcinoma including 112 tumors with glandular elements. Gynecol Oncol 1989;33:49-53.
21. Schwartz SM, Weiss NS. Increased incidence of adenocarcinoma of the cervix in young women in the United States. Am J Epidemiol 1986;124:1045-7.
22. Jones MW, Silverberg SG, Kurman RJ. Well-differentiated villoglandular adenocarcinoma of the uterine cervix: a clinicopathologic study of 24 cases. Im J Gynecol Pathol 1993;12:1-7.
23. Young RH, Scully RE. Villoglandular papillary adenocarcinoma of the uterine cervix. A clinicopathologic analysis of 13 cases. Cancer 1989;63:1773-9.
24. Cooper K, Herrington CS, Lo ES, Evans MF, McGee JO. Integration of human papillomavirus types 16 and 18 in cervical adenocarcinoma. J Clin Pathol 1992;45:382-4.
25. Duggan MA, Benoit JL, McGregor SE, Inoue M, Nation JG, Stuart GC. Adenocarcinoma in situ of the endocervix: human papillomavirus determination by dot blot hybridization and polymerase chain reaction amplification. Int J Gynecol Pathol 1994;13:143-9.
26. Leminen A, Paavonen J, Vesterinen E, Wahlstrom T, Rantala I, Lehtinen M. Human papillomavirus types 16 and 18 in adenocarcinoma of the uterine cervix. Am J Clin Pathol 1991;95:647-52.
27. Hoyhtya M, Fridman R, Komarek D, Porter-Jordan K, Stetler-Stevenson WG, Liotta LA, Liang CM. Immunohistochemical localization of matrix metalloproteinase 2 and its specific inhibitor TIMP-2 in neoplastic tissues with monoclonal antibodies. Int J Cancer 1994;56:500-5.
28. Inoue Y, Abe K, Obata K, et al. Immunohistochemical studies on matrix metalloproteinase-9 (MMP-9) and type-IV collagen in endometrial carcinoma. J Obstet Gynaecol Res 1997;23:139-15.
29. Afzal S, Lalani-el N, Foulkes WD, et al. Matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression and synthetic matrix metalloproteinase-2 inhibitor binding in ovarian carcinomas and tumor cell lines. Lab Invest 1996;74:406-21.
30. Soini Y, Alarakkola E, Autio-Harmainen H. Expression of messenger RNAs for metalloproteinases 2 and 9. type IV collagen, and Laminin in nonneoplastic and neoplastic endometrium. Hum Pathol 1997;28:220-6.
31. Tamakoshi K, Kikkawa F, Nawa A, et al. Characterization of extracellular matrix-degrading proteinase and its inhibitor in gynecologic cancer tissues with clinically different metastatic form. Cancer 1995;76:2565-71.
32. Rosai J. FIGO staging for carcinoma of the cervix uteri. In: Rosai J. Ackerman's surgical pathology. St. Louis. MO: Mosby, 1996:1367.
33. Giorno R. A comparison of two immunoperoxidase staining methods based on the avidin- biotin interaction. Diagn Immunol 1984; 2:161-6.
34. Parks CS, Brigati DJ, Manahan LJ. Automated molecular pathology: one-hour in-situ DNA hybridization. J Histotechnol 1991;14: 219-29.
35. Reed JA, Manahan EJ, Parks CS, Brigati DJ. Complete one-hour immunocytochemistry based on capillary action. Biotechniques 1992;13:434-43.
36. Greene GF, Kitadai Y, Pettaway CA, von Eschenbach AC, Bucana CD, Fidler U. Correlation of metastasis-related gene expression with metastatic potential in human prostate carcinoma cells implanted in nude mice using an in situ messenger RNA hybridization technique. Am J Pathol 1997;150:1571-82.
37. Saigo PE, Cain JM, Kim WS, Gaynor JJ, Johnson K, Lewis JL. Prognostic factors in adenocarcinoma of the uterine cervix. Cancer 1986;57:1584-93.